Study identifier:D798MC00002
ClinicalTrials.gov identifier:NCT06535607
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase II, Multi-Center study to Evaluate the Efficacy and Safety of Volrustomig as Monotherapy or in Combination with Anti-cancer Agents in Participants with Advanced/Metastatic Solid Tumors
cervical cancer
Phase 2
No
-
All
60
Interventional
18 Years - n/a
Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Dec 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Volrustomig This single-arm study consists of multiple sub-studies, divided by indication. | - |